Cross-sectional study describes serotype distribution and vaccine coverage in non-invasive pneumococcal disease in Belgium, suggesting improved adult vaccination is needed.
Non-invasive pneumococcal disease (NIPD) represents a substantial portion of the total pneumococcal disease burden worldwide. In this cross-sectional study, the serotype distribution for isolates originating from NIPD patients in Belgium (2022-2025) is described. Serotype 3 was the serotype with the largest NIPD burden in Belgium (n=178, 12.7%) and detailed analyses revealed that its burden was lower in infants <2 years when compared to older age groups. Pneumococcal conjugate vaccines PCV20 and PCV21 cover approximately 50% to 80%, respectively, of circulating serotypes responsible for NIPD in Belgium, which underlines the importance of improving vaccine uptake in the adult population.
No takes yet. Share an insight, caveat, or question.
Passaris et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: